Emeryville, CA, United States of America

John Tharin Wendell

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Chiron Corporation. Active years: 2008.


% Patents Active = 100.0


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2008

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: John Tharin Wendell: Innovator in Therapeutic Polypeptide Purification

Introduction

John Tharin Wendell is an accomplished inventor based in Emeryville, CA (US). He has made significant contributions to the field of therapeutic polypeptides, particularly in their purification and commercialization. His innovative work has led to the development of methods that enhance the efficiency and effectiveness of therapeutic treatments.

Latest Patents

Wendell holds a patent for the "Chromatographic separation of therapeutic polypeptides." This invention focuses on the purification of therapeutic polypeptides, specifically detailing a method for purifying Interferon β-1b using size exclusion chromatography. Additionally, the patent outlines a method for purifying a polypeptide using size chromatography and provides a framework for the commercialization of such polypeptides.

Career Highlights

Throughout his career, Wendell has worked with notable organizations, including Chiron Corporation. His experience in these companies has allowed him to refine his skills and contribute to advancements in biopharmaceuticals.

Collaborations

Wendell has collaborated with professionals such as Corazon Terciano Victa and Walter Joseph Crosier. These partnerships have played a crucial role in the development and implementation of his innovative methods.

Conclusion

John Tharin Wendell's contributions to the field of therapeutic polypeptides exemplify the impact of innovation in healthcare. His work continues to influence the purification and commercialization of vital therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…